Jonathan Thompson, MD, MS | Froedtert ...

Dr. Jonathan Thompson, MD

Claim this profile

Medical College of Wisconsin

Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
23 drugs studied

Area of expertise

1Lung Cancer
Global Leader
Jonathan Thompson, MD has run 11 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Jonathan Thompson, MD has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
PD-L1 positive

Affiliated Hospitals

Image of trial facility.
Medical College Of Wisconsin
Image of trial facility.
Froedtert Menomonee Falls Hospital

Clinical Trials Jonathan Thompson, MD is currently running

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Image of trial facility.

Nectero EAST System

for Abdominal Aortic Aneurysm

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.
Recruiting1 award Phase 2 & 39 criteria

More about Jonathan Thompson, MD

Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Jonathan Thompson, MD has experience with
  • Pembrolizumab
  • Radiation Therapy
  • Osimertinib
  • Carboplatin
  • Atezolizumab
  • Targeted TKI Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jonathan Thompson, MD specialize in?
Is Jonathan Thompson, MD currently recruiting for clinical trials?
Are there any treatments that Jonathan Thompson, MD has studied deeply?
What is the best way to schedule an appointment with Jonathan Thompson, MD?
What is the office address of Jonathan Thompson, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security